Tags

Type your tag names separated by a space and hit enter

Polestriding Intervention Improves Gait and Axial Symptoms in Mild to Moderate Parkinson Disease.
Arch Phys Med Rehabil. 2017 04; 98(4):613-621.AP

Abstract

OBJECTIVE

To evaluate the effects of 12-week polestriding intervention on gait and disease severity in people with mild to moderate Parkinson disease (PD).

DESIGN

A-B-A withdrawal study design.

SETTING

Outpatient movement disorder center and community facility.

PARTICIPANTS

Individuals (N=17; 9 women [53%] and 8 men [47%]; mean age, 63.7±4.9y; range, 53-72y) with mild to moderate PD according to United Kingdom brain bank criteria with Hoehn & Yahr score ranging from 2.5 to 3.0 with a stable medication regimen and ability to tolerate "off" medication state.

INTERVENTIONS

Twelve-week polestriding intervention with 12-week follow-up.

MAIN OUTCOME MEASURES

Gait was evaluated using several quantitative temporal, spatial, and variability measures. In addition, disease severity was assessed using clinical scales such as Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn & Yahr scale, and Parkinson's Disease Questionnaire-39.

RESULTS

Step and stride lengths, gait speed, and step-time variability were improved significantly (P<.05) because of 12-week polestriding intervention. Also, the UPDRS motor score, the UPDRS axial score, and the scores of UPDRS subscales on walking and balance improved significantly after the intervention.

CONCLUSIONS

Because increased step-time variability and decreased step and stride lengths are associated with PD severity and an increased risk of falls in PD, the observed improvements suggest that regular practice of polestriding may reduce the risk of falls and improve mobility in people with PD.

Authors+Show Affiliations

Center for Adaptive Neural Systems, School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ; Muhammad Ali Parkinson Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ. Electronic address: Narayanan.Krishnamurthi@asu.edu.Banner Sun Health Research Institute, Sun City, AZ.Muhammad Ali Parkinson Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ.Banner Good Samaritan Medical Center, Phoenix, AZ.Banner Good Samaritan Medical Center, Phoenix, AZ.Muhammad Ali Parkinson Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ.Center for Adaptive Neural Systems, School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

27984031

Citation

Krishnamurthi, Narayanan, et al. "Polestriding Intervention Improves Gait and Axial Symptoms in Mild to Moderate Parkinson Disease." Archives of Physical Medicine and Rehabilitation, vol. 98, no. 4, 2017, pp. 613-621.
Krishnamurthi N, Shill H, O'Donnell D, et al. Polestriding Intervention Improves Gait and Axial Symptoms in Mild to Moderate Parkinson Disease. Arch Phys Med Rehabil. 2017;98(4):613-621.
Krishnamurthi, N., Shill, H., O'Donnell, D., Mahant, P., Samanta, J., Lieberman, A., & Abbas, J. (2017). Polestriding Intervention Improves Gait and Axial Symptoms in Mild to Moderate Parkinson Disease. Archives of Physical Medicine and Rehabilitation, 98(4), 613-621. https://doi.org/10.1016/j.apmr.2016.10.002
Krishnamurthi N, et al. Polestriding Intervention Improves Gait and Axial Symptoms in Mild to Moderate Parkinson Disease. Arch Phys Med Rehabil. 2017;98(4):613-621. PubMed PMID: 27984031.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Polestriding Intervention Improves Gait and Axial Symptoms in Mild to Moderate Parkinson Disease. AU - Krishnamurthi,Narayanan, AU - Shill,Holly, AU - O'Donnell,Darolyn, AU - Mahant,Padma, AU - Samanta,Johan, AU - Lieberman,Abraham, AU - Abbas,James, Y1 - 2016/10/27/ PY - 2016/08/08/received PY - 2016/09/19/revised PY - 2016/10/02/accepted PY - 2016/12/17/pubmed PY - 2017/7/14/medline PY - 2016/12/17/entrez KW - Exercise therapy KW - Gait KW - Neurological rehabilitation KW - Parkinson disease KW - Postural balance KW - Rehabilitation SP - 613 EP - 621 JF - Archives of physical medicine and rehabilitation JO - Arch Phys Med Rehabil VL - 98 IS - 4 N2 - OBJECTIVE: To evaluate the effects of 12-week polestriding intervention on gait and disease severity in people with mild to moderate Parkinson disease (PD). DESIGN: A-B-A withdrawal study design. SETTING: Outpatient movement disorder center and community facility. PARTICIPANTS: Individuals (N=17; 9 women [53%] and 8 men [47%]; mean age, 63.7±4.9y; range, 53-72y) with mild to moderate PD according to United Kingdom brain bank criteria with Hoehn & Yahr score ranging from 2.5 to 3.0 with a stable medication regimen and ability to tolerate "off" medication state. INTERVENTIONS: Twelve-week polestriding intervention with 12-week follow-up. MAIN OUTCOME MEASURES: Gait was evaluated using several quantitative temporal, spatial, and variability measures. In addition, disease severity was assessed using clinical scales such as Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn & Yahr scale, and Parkinson's Disease Questionnaire-39. RESULTS: Step and stride lengths, gait speed, and step-time variability were improved significantly (P<.05) because of 12-week polestriding intervention. Also, the UPDRS motor score, the UPDRS axial score, and the scores of UPDRS subscales on walking and balance improved significantly after the intervention. CONCLUSIONS: Because increased step-time variability and decreased step and stride lengths are associated with PD severity and an increased risk of falls in PD, the observed improvements suggest that regular practice of polestriding may reduce the risk of falls and improve mobility in people with PD. SN - 1532-821X UR - https://www.unboundmedicine.com/medline/citation/27984031/Polestriding_Intervention_Improves_Gait_and_Axial_Symptoms_in_Mild_to_Moderate_Parkinson_Disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0003-9993(16)31182-0 DB - PRIME DP - Unbound Medicine ER -